JP2024515809A5 - - Google Patents
Info
- Publication number
- JP2024515809A5 JP2024515809A5 JP2023565986A JP2023565986A JP2024515809A5 JP 2024515809 A5 JP2024515809 A5 JP 2024515809A5 JP 2023565986 A JP2023565986 A JP 2023565986A JP 2023565986 A JP2023565986 A JP 2023565986A JP 2024515809 A5 JP2024515809 A5 JP 2024515809A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- pharmaceutical composition
- composition according
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/029552 WO2022231580A1 (en) | 2021-04-28 | 2021-04-28 | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515809A JP2024515809A (ja) | 2024-04-10 |
| JP2024515809A5 true JP2024515809A5 (https=) | 2024-04-30 |
Family
ID=83847212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565986A Pending JP2024515809A (ja) | 2021-04-28 | 2021-04-28 | Ａｋｒ１ｃ３活性化化合物及び免疫チェックポイント阻害剤の使用による併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240216401A1 (https=) |
| EP (1) | EP4329745A4 (https=) |
| JP (1) | JP2024515809A (https=) |
| KR (1) | KR20240004519A (https=) |
| CN (1) | CN117729917A (https=) |
| AU (1) | AU2021443620A1 (https=) |
| BR (1) | BR112023020922A2 (https=) |
| CA (1) | CA3216896A1 (https=) |
| IL (1) | IL307974A (https=) |
| WO (1) | WO2022231580A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119744168A (zh) * | 2022-09-09 | 2025-04-01 | 深圳艾欣达伟医药科技有限公司 | Ast-3424联用治疗白血病及淋巴瘤 |
| WO2025026214A1 (zh) | 2023-07-28 | 2025-02-06 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变或缺陷阴性癌症、肿瘤患者 |
| CN121646469A (zh) | 2023-09-05 | 2026-03-10 | 深圳艾欣达伟医药科技有限公司 | Ast-3424治疗癌症、肿瘤的给药方案及制药用途 |
| CN121049512A (zh) * | 2024-05-28 | 2025-12-02 | 深圳艾欣达伟医药科技有限公司 | Ast-3424治疗肝癌 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5922791B2 (ja) * | 2012-10-29 | 2016-05-24 | 京セラ株式会社 | 弾性表面波センサ |
| WO2015125652A1 (ja) * | 2014-02-21 | 2015-08-27 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
| EP3390415B1 (en) * | 2015-11-16 | 2020-02-26 | Obi Pharma, Inc. | (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation |
| JP7194022B2 (ja) * | 2016-05-20 | 2022-12-21 | イーライ リリー アンド カンパニー | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
| TW201919644A (zh) * | 2017-09-29 | 2019-06-01 | 台灣浩鼎生技股份有限公司 | 治療血癌的方法 |
| US11098002B2 (en) * | 2019-07-26 | 2021-08-24 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease |
-
2021
- 2021-04-28 KR KR1020237039268A patent/KR20240004519A/ko active Pending
- 2021-04-28 CA CA3216896A patent/CA3216896A1/en active Pending
- 2021-04-28 US US18/288,215 patent/US20240216401A1/en active Pending
- 2021-04-28 AU AU2021443620A patent/AU2021443620A1/en active Pending
- 2021-04-28 JP JP2023565986A patent/JP2024515809A/ja active Pending
- 2021-04-28 CN CN202180097625.2A patent/CN117729917A/zh active Pending
- 2021-04-28 WO PCT/US2021/029552 patent/WO2022231580A1/en not_active Ceased
- 2021-04-28 IL IL307974A patent/IL307974A/en unknown
- 2021-04-28 BR BR112023020922A patent/BR112023020922A2/pt unknown
- 2021-04-28 EP EP21939529.0A patent/EP4329745A4/en active Pending